Next-Generation In Vitro Diagnostics (IVD) Market Report 2026

Next-Generation In Vitro Diagnostics (IVD) Market Overview

• Next-Generation In Vitro Diagnostics (IVD) market size has reached to $117.97 billion in 2025 • Expected to grow to $188.69 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: Rising Demand For Personalized Medicine Fuelling The Growth Of The Next-Generation In Vitro Diagnostics (IVD) Market Due To Increasing Availability Of Genomic Data • Market Trend: Strategic Partnerships Fueling Innovation In Diagnostic Technologies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Next-Generation In Vitro Diagnostics (IVD) Market?

Next-generation in vitro diagnostics (IVD) refers to advanced diagnostic technologies and tools that analyze biological samples, such as blood, saliva, or tissue, outside the body to detect diseases, conditions, or infections with greater accuracy, speed, and personalization. These technologies often integrate innovations such as genomics, AI, digital health platforms, and high-throughput sequencing. The primary purpose of next-generation IVD is to enable earlier, more precise, and patient-specific diagnosis and monitoring of diseases, including cancer, infectious diseases, and genetic disorders. The main product type of next-generation in vitro diagnostics (IVD) includes consumables, instruments, software, and more. Core laboratory diagnostics refers to centralized testing services that analyze a wide range of biological samples using automated, high-throughput instruments and assays. It includes various types such as core laboratory diagnostics, point-of-care testing, molecular diagnostics. It is used for various applications which include oncology or cancer, infectious diseases, diabetes, cardiology, and other diagnostic areas, for varied end users such as hospitals and clinics, diagnostic laboratories, academic and research institutions, and other healthcare providers.

What Is The Next-Generation In Vitro Diagnostics (IVD) Market Growth Forecast?

The next-generation in vitro diagnostics (ivd) market size is expected to see strong growth in the next few years. It will grow to $188.69 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing demand for precision medicine, expansion of genomic testing applications, growing adoption of point-of-care diagnostics, rising healthcare digitization, increasing investments in diagnostic R&D. Major trends in the forecast period include shift toward personalized and companion diagnostics, rapid adoption of point-of-care and decentralized testing, integration of multiplex and high-throughput assays, rising demand for early disease detection and screening, growth of non-invasive and liquid biopsy diagnostics.

Global Next-Generation In Vitro Diagnostics (IVD) Market Segmentation

1) By Product Type: Consumables, Instruments, Software 2) By Diagnostic Modality: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics 3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications 4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users Subsegments: 1) By Consumables: Assay Kits And Reagents, Specimen Bags and Tubes, Seals and Caps 2) By Instruments: Automated Sample Preparation Systems, High-Throughput Molecular Diagnostic Analyzers, Next-Generation Sequencing Platforms, Integrated Diagnostic Workstations And Analysis Platforms, Digital PCR Systems And Advanced Real-Time PCR Instruments 3) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software

What Is The Driver Of The Next-Generation In Vitro Diagnostics (IVD) Market?

The increasing demand for personalized medicine is expected to propel the growth of the next-generation in vitro diagnostics (IVD) market going forward. Precision medicine is a healthcare approach that customizes disease prevention and treatment based on an individual’s genetic profile, environment, and lifestyle. Personalized medicine is rising due to the growing availability of genomic data, which allows healthcare providers to design targeted treatments based on a person’s unique genetic makeup, leading to more effective care. Next-generation in vitro diagnostics (IVD) supports personalized medicine by providing precise molecular and genetic insights that enable tailored treatment and prevention strategies for individual patients. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the next-generation in vitro diagnostics (IVD) industry.

Key Players In The Global Next-Generation In Vitro Diagnostics (IVD) Market

Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc

Global Next-Generation In Vitro Diagnostics (IVD) Market Trends and Insights

Major companies operating in the next-generation in vitro diagnostics (IVD) market are adopting A strategic partnerships approach in next-generation in vitro diagnostics involves collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, enhance diagnostic accuracy, and expand access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, partnered with Genetix, a Colombia-based human genetic diagnosis company, to launch Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative represents a significant advancement in prenatal care in the region, offering expectant parents faster, more reliable, and cost-effective access to advanced genetic screening. The service utilizes Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, suitable for varying sample volumes, and enables Genetix to offer a quality-assured prenatal screening service within Colombia.

What Are Latest Mergers And Acquisitions In The Next-Generation In Vitro Diagnostics (IVD) Market?

In February 2023, SD Biosensor Inc., a South Korea-based company specializing in in-vitro diagnostics, and SJL Partners LLC, a South Korea-based investment company, acquired Meridian Bioscience Inc. for $1.53 billion. With the acquisition, SD Biosensor aims to leverage Meridian's expertise in diagnostic products and raw materials used in immunological and molecular tests for various applications. Meridian Bioscience Inc. is a US-based diagnostic company that provides in vitro diagnostic enzymes.

Regional Outlook

North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Next-Generation In Vitro Diagnostics (IVD) Market?

The next-generation in vitro diagnostics (IVD) market consists of revenues earned by entities providing services such as genomic testing services, molecular diagnostics services, and companion diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation in vitro diagnostics (IVD) market also includes sales of molecular diagnostics kits, proteomics-based diagnostic kits, and NGS sample preparation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.